Celcuity Inc.

Celcuity Inc. is a clinical-stage biotechnology company focused on developing targeted cancer therapies, with gedatolisib as its lead product candidate. The company’s work centers on advancing this drug through clinical development and regulatory review rather than selling commercial products today. Its business model depends on successful trial execution, FDA and other regulatory interactions, and access to financing to support ongoing research and development. Celcuity is based in the United States and operates in a highly regulated, capital-intensive segment of the life sciences industry.

10.55

10.55

— Celcuity Inc.
%
Lead drug candidate development100% Development of gedatolisib and related clinical-stage oncology programs.
Regulatory and clinical operations0% Activities required to run trials, prepare submissions, and interact with regulators.
Supply chain and API management0% Qualification and sourcing of gedatolisib active pharmaceutical ingredient and related materials.

Celcuity does not currently appear to sell commercial products to a broad customer base; instead, its primary...

  • Regulatory agenciesprimary

    The FDA and EMA review clinical data and marketing applications, making timely guidance and approval essential to the program.

  • Clinical trial sites and investigatorsprimary

    Hospitals, research centers, and investigators conduct studies needed to generate efficacy and safety data for gedatolisib.

  • Contract manufacturers and suppliersprimary

    Manufacturing and supply partners provide API and other materials needed to support development and future launch readiness.

  • Future oncology prescribers and patientsemerging

    Oncologists and cancer patients are the eventual commercial audience if the product candidate is approved.

Celcuity is headquartered in the United States and its operating footprint is centered on U.S...

  • •United States is the core operating base and primary regulatory market
  • •FDA interactions are central to clinical development and approval timing
  • •EMA is relevant for foreign regulatory review and potential expansion
  • •API and materials sourcing may involve cross-border imports
  • •Tariffs or trade restrictions could raise development and supply costs

Celcuity’s strategy is centered on advancing gedatolisib through clinical development and securing regulatory approval...

01
Advance gedatolisib through clinical and regulatory milestonesshort-term

Approval is the main value-creation path for a pre-commercial oncology company.

02
Strengthen supply chain resilience for APIshort-term

Single-source or import-dependent supply can disrupt trials and increase costs.

03
Navigate regulatory uncertainty in the U.S. and abroadmedium-term

Delays or disruptions at the FDA or EMA can slow development and increase burn.

Celcuity faces the classic risks of a clinical-stage biotechnology company: trial failure, regulatory delay, and the...

critical

Clinical trial or regulatory failure for gedatolisib

As a single-asset or lead-asset biotech, the company’s value depends heavily on one program.

Scope
Lead oncology pipeline
Materiality
high
high

FDA staffing, funding, or leadership disruptions

The company depends on timely FDA guidance and review of clinical and marketing submissions.

Scope
Clinical development and approval timeline
Materiality
high
high

Financing and liquidity pressure

Development-stage biotech companies typically require repeated external capital raises before commercialization.

Scope
Operating runway and dilution risk
Materiality
high
medium

Tariffs and trade restrictions on imported materials or API

Higher import costs or supply constraints could increase development expenses and delay programs.

Scope
API sourcing and manufacturing inputs
Materiality
medium
Research and development accruals
Can materially change reported operating expenses from quarter to quarter
Inventory and supply chain accounting
May affect balance sheet carrying values and future cost of goods assumptions
Debt and financing arrangements
Affects leverage presentation, interest expense, and liquidity analysis

Celularity Inc

CELU · Pharmaceutical Preparations

CERO THERAPEUTICS HOLDINGS, INC.

CERO · Biological Products, (No Diagnostic Substances)

GENELUX Corp

GNLX · Pharmaceutical Preparations

BriaCell Therapeutics Corp.

BCTX · Pharmaceutical Preparations

Cellectar Biosciences, Inc.

CLRB · Pharmaceutical Preparations

Cadrenal Therapeutics, Inc.

CVKD · Pharmaceutical Preparations

: 28/04/2026